{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:57Z","timestamp":1791928857318,"version":"4.3.4"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n There are gaps in the understanding of the clinical actionability of cardiovascular biomarkers for risk stratification during cardiotoxic chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To gain insights into an N-terminal pro\u2013B-type natriuretic peptide (NT-proBNP)\u2013guided approach for cardioprotection in patients with breast cancer or lymphoma treated with anthracyclines and quantify the feasibility, tolerability, and exploratory efficacy of an NT-proBNP\u2013guided strategy compared with usual care.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The NT-proBNP guide, a multicenter, randomized (stratified 1:1 by cancer type) clinical trial, included 100 participants with breast cancer or lymphoma initiating anthracyclines from March 18, 2021, to October 20, 2023, who were followed up for 12 months.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Study participants in the NT-proBNP\u2013guided arm had biomarker concentrations measured prior to anthracycline initiation (baseline), at each cycle, and at 3, 6, 9, and 12 months. An elevated NT-proBNP concentration triggered the initiation or titration of neurohormonal therapy. Participants in the usual care arm received routine care without prospective monitoring of NT-proBNP concentrations.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were feasibility and safety of the NT-proBNP\u2013guided approach. Feasibility was defined by recruitment, retention, and medication compliance rates. Safety outcomes were assessed according to the Common Terminology Criteria for Adverse Events, version 5.0, at each visit. Exploratory outcomes included differences in blinded, centrally quantified echocardiographic measures and NT-proBNP concentrations between the 2 arms. Analysis was performed on an intention-to-treat approach.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Across 100 participants (mean [SD] age, 52.2 [14.4] years; 86 women [86.0%]), 74 (74.0%) had breast cancer and 26 (26.0%) had lymphoma. At 12 months, the retention rate was 92.7% (89 of 96). In the NT-proBNP\u2013guided arm, 27 participants had NT-proBNP elevations, with a median time from baseline to first elevation of 14 days (IQR, 0-76 days), and a median time between the first NT-proBNP elevation and neurohormonal therapy prescription of 1 day (IQR, 0.5-9 days). There were no significant differences in targeted adverse events between the NT-proBNP\u2013guided (23 events) and usual care (16 events) arms (\n P<\/jats:italic>\n \u2009=\u2009.13). At 3 months, left ventricular ejection fraction (LVEF) was modestly higher in the NT-proBNP\u2013guided arm compared with usual care (mean difference, 2.0% [95% CI, 0.5%-3.5%];\n P<\/jats:italic>\n \u2009=\u2009.007). NT-proBNP concentrations increased in both arms over the study duration, but elevations were slightly attenuated in the NT-proBNP\u2013guided arm.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This randomized clinical trial of an NT-proBNP\u2013guided approach to neurohormonal therapy in patients with cancer treated with anthracyclines demonstrates the feasibility, safety, and potential modest, early improvement in LVEF of a biomarker-guided approach. These findings provide support for further study of an NT-proBNP\u2013guided approach to cardioprotection for patients undergoing cancer treatment.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04737265<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.46201","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:00:32Z","timestamp":1764777632000},"page":"e2546201","source":"Crossref","is-referenced-by-count":10,"title":["Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines"],"prefix":"10.1001","volume":"8","author":[{"given":"Congying","family":"Xia","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Thalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Thalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Thalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizi A.","family":"Jamal","sequence":"additional","affiliation":[{"name":"Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro H.","family":"Armenian","sequence":"additional","affiliation":[{"name":"Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Koropeckyj-Cox","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Thalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyong","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Landsburg","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Clark","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Golec","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Hewitt","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Wilcox","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Rethy","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonyoung","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Thalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunga","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Thalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehoda M.","family":"Martei","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian N.","family":"Lang","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Baim Institute for Clinical Research, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Thalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"5","key":"zoi251250r1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology state-of-the-art review.","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"3","key":"zoi251250r2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jaccao.2023.05.004","article-title":"Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology primer.","volume":"5","author":"Henriksen","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"1","key":"zoi251250r3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy.","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"27","key":"zoi251250r4","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.","volume":"43","author":"Lewinter","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"zoi251250r5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaccao.2024.07.010","article-title":"Preventing cardiac damage in patients treated for breast cancer and lymphoma: the PROACT clinical trial.","volume":"6","author":"Austin","year":"2024","journal-title":"JACC CardioOncol"},{"key":"zoi251250r6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejca.2022.03.024","article-title":"Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: a systematic review & bayesian network meta-analysis.","volume":"169","author":"Sayed","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi251250r7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction.","volume":"9","author":"Demissei","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"zoi251250r8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/cncr.33292","article-title":"Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort.","volume":"127","author":"Dixon","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"zoi251250r9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"zoi251250r10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"zoi251250r11","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"20","key":"zoi251250r12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"17","key":"zoi251250r13","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"zoi251250r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"issue":"15","key":"zoi251250r15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","article-title":"Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up.","volume":"135","author":"Narayan","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"zoi251250r16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"zoi251250r17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2147\/PPA.S249079","article-title":"Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Medication Adherence Scale (PMAS).","volume":"14","author":"Peipert","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"13","key":"zoi251250r19","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1200\/JCO.2015.65.5860","article-title":"Accuracy of adverse event ascertainment in clinical trials for pediatric acute myeloid leukemia.","volume":"34","author":"Miller","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi251250r20","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY Trial.","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"zoi251250r21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.clinthera.2016.03.011","article-title":"Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials.","volume":"38","author":"Basch","year":"2016","journal-title":"Clin Ther"},{"issue":"21","key":"zoi251250r22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I\u2013guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE Trial.","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation"},{"issue":"36","key":"zoi251250r23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"zoi251250r24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(23)00637-X","article-title":"Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial.","volume":"25","author":"Armenian","year":"2024","journal-title":"Lancet Oncol"},{"issue":"23","key":"zoi251250r25","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"zoi251250r26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaccao.2024.07.015","article-title":"Carvedilol to improve cardiac remodeling in anthracycline-exposed childhood cancer survivors: subgroup analysis of COG ALTE1621.","volume":"6","author":"Armenian","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"1","key":"zoi251250r27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.18.00313","article-title":"Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children\u2019s Oncology Group.","volume":"37","author":"Getz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi251250r28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide\u2013based screening and collaborative care for heart failure: the STOP-HF randomized trial.","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"zoi251250r18","unstructured":"CTCAE and adverse event reporting. National Cancer Institute. Accessed October 23, 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events - ctcae"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842214\/xia_2025_oi_251250_1764012948.3642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:00:33Z","timestamp":1764777633000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842214"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.46201","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}